Form 4: BioCryst CEO Stonehouse Reports Routine Share Withholding

BioCryst Pharmaceuticals CEO Jon P. Stonehouse reported the withholding of 61,793 common shares for tax obligations related to vested restricted stock units.

Summary

• Jon P. Stonehouse, Chief Executive Officer and Director of BIOCRYST PHARMACEUTICALS INC (BCRX), reported a transaction on December 19, 2025.
• The transaction involved the disposition of 61,793 shares of Common Stock at a price of $7.41 per share.
• This disposition was an 'F' transaction code, indicating shares withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted restricted stock units.
• The transaction does not represent a sale by the reporting person.
• Following this transaction, Jon P. Stonehouse directly beneficially owns 1,323,429 shares of Common Stock.
• Additionally, 40,000 shares are indirectly beneficially owned by his wife as co-trustee of the Caroline Stonehouse Irrevocable Trust, and another 40,000 shares are indirectly beneficially owned by his wife as co-trustee of the Samuel Stonehouse Irrevocable Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While shares were 'disposed of,' it was a non-discretionary tax withholding event related to RSU vesting, not a sale by the executive. This indicates the executive's compensation plan is progressing as expected.

Positives

• The transaction represents the vesting of previously granted restricted stock units, indicating that performance or time-based conditions for executive compensation have been met.
• The disposition was for tax withholding purposes, not a discretionary sale by the CEO, which can be viewed as a neutral to slightly positive signal regarding management's long-term commitment.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The shares were withheld by the Issuer to satisfy required tax withholding obligations in connection with the vesting of previously granted restricted stock units.
• This transaction does not represent a sale by the reporting person.

Industry Context

This routine insider transaction, related to executive compensation and tax obligations, is common across publicly traded companies and does not reflect specific industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: This is a routine executive compensation event and tax withholding, which typically has minimal direct impact on shareholders. It confirms the vesting of previously granted equity awards.
• Employees: No direct impact on general employees is indicated by this filing.

Key Dates

Keywords

BioCryst Pharmaceuticals, BCRX, Jon P. Stonehouse, Insider Transaction, Form 4, Restricted Stock Units, Tax Withholding, Executive Compensation